Skip to main content

Table 2 Univariate and multivariate analysis of prognostic factors in patients with (PFS)

From: Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience

ParametersMedian (months)95% CIP
value
Hazard ratio95% CIP
value
Age  .821  
65 (n = 74)3.82.7–4.9    
  > 65 (n = 44)3.32.3–4.2    
Gender  .540  
 Male (n = 58)2.82.2–3.4    
 Female (n = 60)4.02.8–5.3    
ICD-10 cancer site  .011   
 C22.1 – ICCA (n = 86)3.92.6–5.2 0.8770.321–2.397.799
 C23/C24.9 –GB/others (n = 18)2.72.4–3.0 1.5680.510–4.819.433
 C24.0 – ECCA (n = 9)8.00.0–24.4 1  
 C24.1 – Ampullary (n = 5)3.31.7–4.8 1.5190.378–6.110.556
Performance status  .260  
 0/1 (n = 102)3.82.7–4.9    
 2/3 (n = 16)2.71.8–3.7    
NLR  .020   
7.45 (n = 100)3.82.8–4.8 1  
  > 7.45 (n = 18)2.41.4–3.3 1.9821.040–3.777.038
MLR  .028   
0.28 (n = 40)5.94.3–7.4 1  
  > 0.28 (n = 78)2.92.5–3.3 1.2630.737–2.162.396
PLR  .396  
136.4 (n = 47)4.82.9–6.8    
  > 136.4 (n = 71)3.12.7–3.5    
Albumin (g/dL)  .777  
3.5 (n = 33)3.12.6–3.6    
  > 3.5 (n = 72)3.92.8–4.9    
ALT (U/L)  .484  
36 (n = 68)3.22.3–4.0    
  > 36 (n = 49)4.32.8–5.7    
Bilirubin (mg/dL)  .622  
1.3 (n = 89)3.82.6–5.0    
  > 1.3 (n = 28)3.32.4–4.1    
ALP (U/L)  .060  
94 (n = 30)5.92.5–9.2    
  > 94 (n = 82)2.82.4–3.3    
Creatinine (mg/dL)  .612  
1.27 (n = 115)3.62.6–4.6    
  > 1.27 (n = 3)2.70.0–6.7    
CA19–9 (U/mL)  .263  
37 (n = 35)2.92.3–3.4    
  > 37 (n = 82)4.32.7–5.9    
CEA (ng/mL)  .347  
5 (n = 64)4.33.0–5.7    
  > 5 (n = 54)3.22.7–3.6    
Biliary drainage  .047   
 None (n = 88)3.22.4–4.0 1.3960.497–3.921.527
 Internal drainage(n = 8)7.63.2–12.1 1  
 PTCD (n = 19)3.42.8–4.0 0.7110.244–2.066.531
 Both (n = 3)1.30.5–2.1 8.7101.831–41.445.007
Tumor involvement
 Primary tumor  .081  
  No (n = 8)2.62.1–3.1    
  Yes (n = 110)3.82.7–4.8    
 Regional LAP  .679  
  No (n = 42)3.92.6–5.1    
  Yes (n = 76)3.22.3–4.1    
 Lung  <.001   
  No (n = 95)4.33.0–5.6 1  
  Yes (n = 23)2.62.2–3.1 1.6780.905–3.112.101
 Bone  .181   
  No (n = 105)3.82.7–4.8    
  Yes (n = 13)3.42.3–4.5    
 Liver  .034   
  No (n = 69)4.32.2–6.3 1  
  Yes (n = 49)3.22.1–4.2 1.2320.759–1.998.398
 Peritoneum  .138  
  No (n = 96)3.92.5–5.2    
  Yes (n = 22)3.12.5–3.7    
 Distant LAP  .785  
  No (n = 102)3.42.3–4.5    
  Yes (n = 16)3.62.5–4.7    
 Tumor Response  <.0001   
  CR/RR (n = 15)14.17.9–20.2 1  
  SD (n = 41)7.66.4–8.8 1.8190.824–4.015.139
  PD (n = 48)2.52.4–2.7 55.55619.467–158.550<.0001
  N/A (n = 14)1.30.8–1.9 63.90520.396–200.232<.0001
  1. CI Confidence interval, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, N/A Not assessed, ALP Alkaline phosphatase, ALT Alanine aminotransferase, NLR Neutrophil to lymphocyte ratio, MLR Monocyte to lymphocyte ratio, PLR Platelet to lymphocyte ratio, LAP Lymphadenopathy, PTCD Percutaneous transhepatic cholangiography drainage, ICCA Intrahepatic cholangiocarcinoma, ECCA Extrahepatic cholangiocarcinoma, GB Gallbladder